Zura Bio holder buys 2M shares in offering

Zura Bio Ltd reported that affiliated entity AI Biotechnology LLC, a 10% owner, bought 2,000,000 Class A Ordinary Shares of Zura Bio.

Accepted by SEC EDGAR 03/02/2026 - 05:55 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Zura Bio Ltd reported that affiliated entity AI Biotechnology LLC, a 10% owner, bought 2,000,000 Class A Ordinary Shares of Zura Bio.

The shares were acquired at $6.25 per share in a registered offering by the company, increasing AI Biotechnology LLC’s direct holdings to 6,552,725 shares. Related entities, including Access Industries Holdings LLC, Access Industries Management, LLC and Len Blavatnik, may be deemed beneficial owners through their control structure but each disclaims beneficial ownership beyond any pecuniary interest.

Insider Trade Summary

Net Buyer: 2,000,000 shares

Net Buy 1 txn

Insider AI Biotechnology LLC, Access Industries Holdings LLC, ACCESS INDUSTRIES MANAGEMENT, LLC, Blavatnik Len

Role 10% Owner | 10% Owner | 10% Owner | 10% Owner

Bought 2,000,000 shs ($12.50M)

Type	Security	Shares	Price	Value
Purchase	Class A Ordinary Shares	2,000,000	$6.25	$12.50M

Holdings After Transaction: Class A Ordinary Shares — 6,552,725 shares (Direct)

Footnotes (2)

1. F1. Shares of Class A Ordinary Shares acquired pursuant to a registered offering of Class A Ordinary Shares by the Issuer.
2. F2. The securities reported are held directly by AI Biotechnology LLC ("AIB") and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, and (iii) AIH owns all of the voting units of AIB. Each of AIH, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Zura Bio (ZURA) report in this Form 4?

Zura Bio reported that AI Biotechnology LLC acquired 2,000,000 Class A Ordinary Shares. The purchase increased its direct holdings to 6,552,725 shares, reflecting a significant additional investment by a 10% beneficial owner associated with Access Industries entities and Len Blavatnik.

At what price were the new Zura Bio (ZURA) shares purchased?

The 2,000,000 Class A Ordinary Shares were acquired at $6.25 per share. This price comes from a registered offering by Zura Bio, rather than open-market trading, indicating participation in a primary share issuance by the company.

Who is the primary holder of the Zura Bio (ZURA) shares reported in this Form 4?

The securities are held directly by AI Biotechnology LLC. Access Industries Holdings LLC, Access Industries Management, LLC and Len Blavatnik may be deemed beneficial owners through control relationships but each disclaims beneficial ownership beyond any pecuniary interest.

How many Zura Bio (ZURA) shares does AI Biotechnology LLC own after this transaction?

After acquiring 2,000,000 additional shares, AI Biotechnology LLC holds 6,552,725 Class A Ordinary Shares. This figure reflects its direct ownership position following participation in the registered offering disclosed in the Form 4 filing.

How are Access Industries and Len Blavatnik connected to the Zura Bio (ZURA) shares?

Access Industries Holdings LLC, Access Industries Management, LLC and Len Blavatnik may be deemed beneficial owners because of their control over AI Biotechnology LLC. However, each party disclaims beneficial ownership of the reported securities beyond its or his pecuniary interest.

Was the Zura Bio (ZURA) insider transaction an open-market trade or part of an offering?

The shares were acquired pursuant to a registered offering of Class A Ordinary Shares by Zura Bio. This means AI Biotechnology LLC bought directly in a company share issuance, rather than acquiring the stock through open-market purchases on an exchange.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AI Biotechnology LLC

(Last) (First) (Middle)

C/O ACCESS INDUSTRIES, INC.

40 WEST 57TH STREET, 28TH FLOOR

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zura Bio Ltd [ ZURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	02/26/2026		P(1)		2,000,000(1)	A	$6.25	6,552,725	D(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

AI Biotechnology LLC

(Last) (First) (Middle)

C/O ACCESS INDUSTRIES, INC.

40 WEST 57TH STREET, 28TH FLOOR

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Access Industries Holdings LLC

(Last) (First) (Middle)

C/O ACCESS INDUSTRIES, INC.

40 WEST 57TH STREET, 28TH FLOOR

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

ACCESS INDUSTRIES MANAGEMENT, LLC

(Last) (First) (Middle)

C/O ACCESS INDUSTRIES, INC.

40 WEST 57TH STREET, 28TH FLOOR

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Blavatnik Len

(Last) (First) (Middle)

C/O ACCESS INDUSTRIES, INC.

40 WEST 57TH STREET, 28TH FLOOR

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. Shares of Class A Ordinary Shares acquired pursuant to a registered offering of Class A Ordinary Shares by the Issuer.

2. The securities reported are held directly by AI Biotechnology LLC ("AIB") and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, and (iii) AIH owns all of the voting units of AIB. Each of AIH, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.

	/s/ Alejandro Moreno for AI Biotechnology LLC	03/02/2026
	/s/ Alejandro Moreno for Access Industries Holdings LLC	03/02/2026
	/s/ Alejandro Moreno for Access Industries Management, LLC	03/02/2026
	/s/ Alejandro Moreno, as Attorney-in-Fact for Mr. Blavatnik	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.